Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic

Abstract

Purpose:

Aromatase inhibitors (AIs) are routinely used as first-line adjuvant treatment of breast cancer in postmenopausal women with hormone receptor positive tumors. The current recommended length of treatment with an AI is 5 years. Arthralgias have been frequently cited as the primary reason for discontinuation of AI therapy. Various treatment strategies are proposed in literature, but a standardized treatment algorithm has not been established. The initial purpose of this study was to describe the incidence and management of AI-induced arthralgias in patients treated at Kellogg Cancer Center (KCC). Further evaluation led to the development and the implementation of a treatment algorithm and electronic medical record (EMR) documentation tools.

Methods:

The retrospective chart review included 206 adult patients with hormone receptor positive breast cancer who were receiving adjuvant therapy with an AI. A multidisciplinary treatment team consisting of pharmacists, collaborative practice nurses, and physicians met to develop a standardized treatment algorithm and corresponding EMR documentation tool. The treatment algorithm and documentation tool were developed after the study to better monitor and proactively treat patients with AI-induced arthralgias.

Results/conclusions:

The overall incidence of arthralgias at KCC was 48% (n = 98/206). Of these patients, 32% were documented as having arthralgias within the first 6 months of therapy initiation. Patients who reported AI-induced arthralgias were younger than patients who did not report AI-induced arthralgias (61 vs. 65 years, p = 0.002). There was no statistical difference in the incidence of arthralgias in patients with a history of chemotherapy (including taxane therapy) compared to those who did not receive chemotherapy (p = 0.352). Of patients presenting with AI-induced arthralgias, 41% did not have physician-managed treatment documented in the EMR. A standardized treatment algorithm and electronic chart documentation tools were then developed by the multidisciplinary team.

Keywords

Aromatase inhibitors arthralgias breast cancer

Get full access to this article

View all access options for this article.

References

American Cancer Society. ‘How many women get breast cancer?’, http://www.cancer.org (accessed June 2011).

WebMD. ‘Types of breast cancer: ER Positive, HER2 positive, and triple negative’, http://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive (accessed April 2010).

Sehdev

Martin

Sideris

. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol 2009; 16(Suppl 2): S14–S23.

Morales

Pans

Verschueren

. Perspective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26: 3147–3152.

Coleman

Bolten

Lansdown

. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendation. Cancer Treat Rev 2008; 34: 275–282.

Hershman

. Getting a grip on aromatase inhibitor-associated arthralgias. J Clin Oncol 2008; 26: 3120–3121.

Mao

Stricker

Bruner

. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009; 115: 3631–3639.

Crew

Greenlee

Capodice

. Prevalence of joint symptoms in post menopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25: 3877–3883.

Sestak

Cuzick

Sapunar

. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9: 866–872.

10.

Hess

. Retrospective studies and chart reviews. Respir Care 2004; 49(10): 1171–1174.

11.

The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early breast cancer: first results of the ATAC randomized trial. The Lancet 2002; 349(9324): 2131–2139.

12.

Cuzick

Sestak

Cella

. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008; 9: 1143–1148.

13.

CTCAE. Common terminology criteria for adverse events v 3.0, National Institutes of Health, National Cancer Institute, August 2006.